WIN 54954

SKU: orb1688384

Description

WIN 54954 is an orally bioavailable antiviral compound that suppresses Coxsackievirus replication by inhibiting viral transcription or translation. It serves as a useful research tool for studying picornavirus infections in both in vitro and in vivo experimental models.

Research Area

Epigenetics & Chromatin, Immunology & Inflammation, Infectious Disease & Virology

Key Properties

• CAS Number: 107355-45-3
• MW: 383.27
• Purity: 98.98% (May vary between batches)
• Formula: C₁₈H₂₀Cl₂N₂O₃
• SMILES: Cc1cc(CCCCCOc2c(Cl)cc(cc2Cl)C2=NCCO2)on1
• Target: Virus Protease,Antiviral
• Solubility: DMSO:80 mg/mL (208.73 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (8.61 mM)

Bioactivity

• In Vivo:
  A single gastric dose of WIN 54954 at daily doses of 2 and 100 mg/kg protected 50% of mice from paralysis after infection with Coxsackie virus A-9 and ECHO virus-9, respectively (PD50).
  Read more...
• In Vitro:
  WIN 54954 reduced plaque formation by 50 of 52 serotypes of rhinovirus (MIC range: 0.007 to 2.2 μg/ml). A concentration of 0.28 μg/ml effectively inhibited 80% of the 52 serotypes (EC80). WIN 54954 also effectively inhibited 15 commonly isolated enteroviruses, with an EC80 of 0.06 μg/ml.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Antiviral

Compound Identifiers

PubChem CID

441048